Celltrion nears additional contract with major U.S. PBM
Celltrion is in the final stages of formulary listing negotiations with a major U.S. pharmacy benefit manager (PBM) for its high-margin follow-up biosimilar portfolio, aiming to conclude an additional contract within the fourth quarter of this year. The company plans to continue its earnings growth trajectory in the fourth quarter following record-breaking p..